These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. SGLT2 Inhibitors and the Diabetic Kidney. Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829 [TBL] [Abstract][Full Text] [Related]
10. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Thomas MC; Cherney DZI Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034 [TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Zou H; Zhou B; Xu G Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711 [TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events. Sarzani R; Giulietti F; Di Pentima C; Spannella F Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1622-1632. PubMed ID: 32631704 [TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. Alicic RZ; Johnson EJ; Tuttle KR Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460 [TBL] [Abstract][Full Text] [Related]
14. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Dekkers CCJ; Gansevoort RT; Heerspink HJL Curr Diab Rep; 2018 Mar; 18(5):27. PubMed ID: 29589183 [TBL] [Abstract][Full Text] [Related]
15. New Therapeutic Strategies for Type 2 Diabetes Yehya A; Sadhu AR Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014 [TBL] [Abstract][Full Text] [Related]
16. Are SGLT2 Inhibitors Ready for Prime Time for CKD? Pecoits-Filho R; Perkovic V Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920 [No Abstract] [Full Text] [Related]
17. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Layton AT; Vallon V Am J Physiol Renal Physiol; 2018 May; 314(5):F969-F984. PubMed ID: 29361669 [TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy. Takenaka T; Kishimoto M; Ohta M; Tomonaga O; Suzuki H Diab Vasc Dis Res; 2017 May; 14(3):258-261. PubMed ID: 28467199 [TBL] [Abstract][Full Text] [Related]
19. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Schernthaner G; Mogensen CE; Schernthaner GH Diab Vasc Dis Res; 2014 Sep; 11(5):306-23. PubMed ID: 25116004 [TBL] [Abstract][Full Text] [Related]
20. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]